Virtual Library

Start Your Search

John English



Author of

  • +

    FP09 - Screening and Early Detection (ID 175)

    • Event: WCLC 2020
    • Type: Posters (Featured)
    • Track: Screening and Early Detection
    • Presentations: 1
    • Moderators:
    • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
    • +

      FP09.01 - Economic Impact of Screening Selection with the PLCOm2012 Risk Model Versus USPSTF-Guidelines in the International Lung Screening Trial (ILST)  (ID 2400)

      00:00 - 00:00  |  Author(s): John English

      • Abstract
      • Slides

      Introduction

      Screening protocols that use model-estimated risk for selection are thought to improve the efficiency of lung cancer screening by reducing the number needed to screen and detecting more lung cancers. Since risk selection enriches screening populations with greater age and tobacco smoke exposure, some hypothesize that screening with model-based risk selection would be less cost-effective than more broadly defined selection criteria such as those defined by the USPSTF. The objective of this study is to examine the costs and cost-effectiveness of selection with the PLCOm2012 risk model versus USPSTF-based selection in the International Lung Screening Trial (ILST).

      Methods

      The International Lung Screening Trial offered enrollment to participants that either had a PLCOm2012 lung cancer risk ≥1.51%/6 years or met the USPSTF criteria for screening selection. A cohort-based simulation model was developed to estimate the lifetime economic impact of screening PLCOm2012+ve but not PLCOm2012-ve/USPSTF+ve compared with screening USPSTF+ve but not PLCOm2012+ve/USPSTF-ve. We used risk-matched screening costs from the PanCan Early Detection of Lung Cancer study (PanCan) to calculate the post-baseline annual screening costs for each of the selection subgroups in the ILST and estimated the additional costs per quality adjusted life years (QALYs) with a published simulation model based on the NLST and PanCan screening studies.

      Results

      At the time of analysis 11,166 individuals registered in the study, with an interest in participating in lung cancer screening at one of seven coordinating sites in Canada, Australia and Hong Kong. Of these, 4282 enrolled in the study; 991 (23.1%) were exclusively selected by the PLCOm2012 criteria, 597 (13.9%) were exclusively selected by the UPSPSTF criteria and 2694 (62.9%) were selected by both criteria. The annual screening costs for the USPSTF-exclusive group were slightly higher than the rest of the cohort ($514 versus $508; p<0.05) and were thus held constant for simulation of the base-case scenario in the cost-effectiveness analysis. Compared with the PLCOm2012-selected cohort, the risk ratios for developing lung cancer were significantly lower for the proportion of the ILST that only met the USPSTF selection criteria (0.22; 95%CI: 0.07-0.71) and PLCO-exclusive subgroup had similar lung cancer risk ratios as the rest of the cohort (1.31; 95%CI: 0.82-2.08). Under the assumption that the early-stage lung cancers detected in the PLCOm2012-exclusive cohort would go undetected in the USPSTF-guided strategy – and the published modelling assumptions – the PLCOm2012-guided selection strategy is estimated to cost an additional $170 and result in an additional 0.3 QALYs over the comparator. The incremental cost-effectiveness ratio appears to be cost-effective at $561/QALY. The results were sensitive to lung cancer treatment costs and modifiable heart and lung health risks such as prevention and improved quality of life through earlier and better management of COPD; while insensitive to annual screening costs.

      Conclusion

      When risk-model informed screening selection is compared to the USPSTF selection guidelines, risk-model selection introduces minor costs but may prove cost-saving in the long-term, and lead to improved QALY gains. Updates to immunotherapy treatment costs are likely to counterbalance any additional costs associated with model-based risk selection.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.